

1 KAMALA D. HARRIS
Attorney General of California
2 KENT D. HARRIS
Supervising Deputy Attorney General
3 PHILLIP L. ARTHUR
Deputy Attorney General
4 State Bar No. 238339
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 322-0032
Facsimile: (916) 327-8643

7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

11 In the Matter of the First Amended Accusation
Against:

Case No. 5527

12 **LIVE OAK PHARMACY**
13 **RANJIT SINGH, Owner/Pharmacist-In-Charge**
14 **9970 Live Oak Blvd.**
Live Oak, CA 95953

FIRST AMENDED ACCUSATION

15 **Original Pharmacy Permit No. PHY 45317**

16 **and**

17 **RANJIT SINGH**
18 **3215 Pennington Road**
Live Oak, CA 95953

19 **Original Pharmacist License No. RPH 46870**

20 Respondents.

21 Complainant alleges:

22 **PARTIES**

23 1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity
24 as the Executive Officer of the Board of Pharmacy ("Board"), Department of Consumer Affairs.

25 2. On or about April 12, 2001, the Board issued Original Pharmacy Permit Number
26 PHY 45317 to Ranjit Singh ("Respondent"), owner and pharmacist-in-charge of Live Oak
27 Pharmacy. The original pharmacy permit was in full force and effect at all times relevant to the
28

1 charges brought herein, and was canceled on January 3, 2017.

2 3. On or about March 7, 1994, the Board issued Original Pharmacist License Number
3 RPH 46870 to Respondent. The original pharmacist license was in full force and effect at all
4 times relevant to the charges brought herein and will expire on March 31, 2018, unless renewed.

5 **JURISDICTION**

6 4. This Accusation is brought before the Board under the authority of the following
7 laws. All section references are to the Business and Professions Code (Code) unless otherwise
8 indicated.

9 5. Code section 4300 states, in pertinent part:

10 (a) Every license issued may be suspended or revoked.

11 (b) The board shall discipline the holder of any license issued by the
12 board, whose default has been entered or whose case has been heard by the board and
found guilty, by any of the following methods:

13 (1) Suspending judgment.

14 (2) Placing him or her upon probation.

15 (3) Suspending his or her right to practice for a period not exceeding one
16 year.

17 (4) Revoking his or her license.

18 (5) Taking any other action in relation to disciplining him or her as the
board in its discretion may deem proper

19 6. Code section 4300.1 states:

20 The expiration, cancellation, forfeiture, or suspension of a board-issued
21 license by operation of law or by order or decision of the board or a court of law, the
22 placement of a license on a retired status, or the voluntary surrender of a license by a
23 licensee shall not deprive the board of jurisdiction to commence or proceed with any
investigation of, or action or disciplinary proceeding against, the licensee or to render
a decision suspending or revoking the license.

24 7. Section 4307(a) of the Code states that:

25 Any person who has been denied a license or whose license has been
26 revoked or is under suspension, or who has failed to renew his or her license while it
27 was under suspension, or who has been a manager, administrator, owner member,
28 officer, director, associate, or partner of any partnership, corporation, firm, or
association whose application for a license has been denied or revoked, is under
suspension or has been placed on probation, and while acting as the manger,
administrator, owner, member, officer, director, associate, or partner had knowledge

1 or knowingly participated in any conduct for which the license was denied, revoked,
2 suspended, or placed on probation, shall be prohibited from serving as a manger,
3 administrator, owner, member, officer, director, associate, or partner of a licensee as
4 follows:

5 (1) Where a probationary license is issued or where an existing license is
6 placed on probation, this prohibition shall remain in effect for a period not to exceed
7 five years.

8 (2) Where the license is denied or revoked, the prohibition shall continue
9 until the license is issued or reinstated.

10 **STATUTORY AND REGULATORY PROVISIONS**

11 8. Code section 4301 states, in pertinent part:

12 The board shall take action against any holder of a license who is guilty
13 of unprofessional conduct or whose license has been procured by fraud or
14 misrepresentation or issued by mistake. Unprofessional conduct shall include, but is
15 not limited to, any of the following:

16 . . .

17 (o) Violating or attempting to violate, directly or indirectly, or assisting in
18 or abetting the violation of or conspiring to violate any provision or term of this
19 chapter or of the applicable federal and state laws and regulations governing
20 pharmacy, including regulations established by the board or by any other state or
21 federal regulatory agency

22 9. Code section 4113, subdivision (c), states that, “[t]he pharmacist-in-charge shall be
23 responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining
24 to the practice of pharmacy.”

25 10. Health and Safety Code section 11153, subdivision (a), states, in pertinent part:

26 A prescription for a controlled substance shall only be issued for a
27 legitimate medical purpose by an individual practitioner acting in the usual course of
28 his or her professional practice. The responsibility for the proper prescribing and
dispensing of controlled substances is upon the prescribing practitioner, but a
corresponding responsibility rests with the pharmacist who fills the prescription

11. California Code of Regulations, title 16, section 1709.1, subdivision (a), states that,
“[t]he pharmacist-in-charge of a pharmacy shall be employed at that location and shall have
responsibility for the daily operation of the pharmacy.”

///

///

1 12. California Code of Regulations, title 16, section 1761, states:

2 (a) No pharmacist shall compound or dispense any prescription which
3 contains any significant error, omission, irregularity, uncertainty, ambiguity or
4 alteration. Upon receipt of any such prescription, the pharmacist shall contact the
prescriber to obtain the information needed to validate the prescription.

5 (b) Even after conferring with the prescriber, a pharmacist shall not
6 compound or dispense a controlled substance prescription where the pharmacist
knows or has objective reason to know that said prescription was not issued for a
legitimate medical purpose.

7 **COST RECOVERY**

8 13. Code section 125.3 provides, in pertinent part, that a Board may request the
9 administrative law judge to direct a licentiate found to have committed a violation or violations of
10 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
11 enforcement of the case.

12 **CONTROLLED SUBSTANCES**

13 14. "Methadone" is a Schedule II controlled substance as designated by Health and
14 Safety Code section 11055, subdivision (c)(14).

15 15. "Morphine Sulfate IR (immediate release)" is a Schedule II controlled substance as
16 designated by Health and Safety Code section 11055, subdivision (b)(1)(L).

17 16. "Morphine Sulfate ER (extended release)" is a Schedule II controlled substance as
18 designated by Health and Safety Code section 11055, subdivision (b)(1)(L).

19 17. "Oxycodone" is a Schedule II controlled substance as designated by Health and
20 Safety Code section 11055, subdivision (b)(1)(M).

21 18. "Hydromorphone" is a Schedule II controlled substance as designated by Health and
22 Safety Code section 11055, subdivision (b)(1)(J).

23 19. "Fentanyl" is a Schedule II controlled substance as designated by Health and Safety
24 Code section 11055, subdivision (c)(8).

25 20. "Norco" is a compound consisting of 10 mg hydrocodone bitartrate, also known as
26 dihydrocodeinone, and 325 mg acetaminophen per tablet. At the time of the incidents described
27 below, Norco was classified as a Schedule III controlled substance pursuant to Health and Safety
28

1 Code section 11056, subdivision (e)(4).¹

2 **STATEMENT OF FACTS**

3 21. On or about November 15, 2013, the Medical Board of California revoked Dr. A. L.'s
4 physician's and surgeon's certificate. The revocation was stayed and Dr. A. L. was placed on
5 probation for five years. Dr. A. L. was also suspended from the practice of medicine for thirty
6 days. Dr. A. L. was charged in the disciplinary proceeding with prescribing excessive amounts
7 and high doses of controlled substances.

8 22. The Drug Enforcement Administration had commenced an investigation of Dr. A. L.
9 and the pharmacies that filled prescriptions for Dr. A. L.'s patients (the investigation was
10 subsequently halted due to the death of Dr. A. L. in December 2013).

11 23. A Board analyst ran CURES² reports showing Dr. A. L.'s prescribing habits. Live
12 Oak Pharmacy was identified as one of two pharmacies dispensing the most prescriptions for Dr.
13 A. L.'s patients. Dr. A. L.'s practice was located in Colusa, California, approximately 32.9 miles
14 from Live Oak Pharmacy.

15 24. On or about September 1, 2014, a Board Inspector obtained CURES information from
16 September 1, 2011 to September 5, 2014, for Live Oak Pharmacy and three other pharmacies
17 located in close proximity to Live Oak Pharmacy. The inspector selected certain patients,
18 identified in the CURES report for Live Oak Pharmacy to review based on the distance the
19 patients lived from the pharmacy, the quantities of controlled substances prescribed, the
20 combinations of controlled substances prescribed, and whether the individuals were patients of
21 Dr. A. L. The inspector also requested CURES data from September 1, 2011 to September 5,
22 2014, for each patient selected, including the following fourteen patients: TB, PM, JB, DS, MH,
23 RB, BN, KS, DM, CF, DB, JY, TF1, and TF2.

24 ///

25 _____
26 ¹ Hydrocodone has been rescheduled from a Schedule III to Schedule II controlled
substance via the Controlled Substances Act (21 CFR Part 1308 § 1308.12; 21 U.S.C. 812 (c).)

27 ² CURES is a database containing information on Schedule II through IV controlled
28 substances dispensed in California. It is a valuable investigative, preventive, and educational tool
for the healthcare community, regulatory boards, and law enforcement.

1 25. On or about September 3, 2014, the inspector and another representative of the Board
2 conducted an inspection of Live Oak Pharmacy during which they were assisted by Respondent.
3 The inspector requested patient profiles for the above fourteen patients, and found in reviewing
4 the profiles that nine of the fourteen patients were from out of the area, including Shasta Lake,
5 California (113 miles away) and Granite Bay, California (fifty-six miles away). The inspector
6 obtained several hardcopy prescriptions for thirteen of the fourteen patients and requested drug
7 utilization reports (DUR's) for Dr. A. L. from January 1, 2012 to September 3, 2014. On or about
8 September 24, 2014, the inspector received the DUR's from Respondent.

9 26. The inspector reviewed the CURES reports for Live Oak Pharmacy and the three
10 other pharmacies located in close proximity to Live Oak Pharmacy, and created spreadsheets
11 based on the data. The inspector compared the total number of controlled substances dispensed
12 by the pharmacies with the total number of controlled substances written by Dr. A. L. for the
13 period from September 1, 2011 to September 5, 2014, and found that Live Oak Pharmacy
14 dispensed more of Dr. A. L.'s prescriptions than any of the other pharmacies.

15 27. The inspector created a chart showing the round trip distance from the fourteen
16 patients' homes to Dr. A. L.'s office in Colusa and Live Oak Pharmacy. Only five of the fourteen
17 patients lived in Live Oak Pharmacy's trade area, defined by Respondent as Yuba City, Gridley,
18 and Live Oak. The shortest distance traveled for the fourteen patients was 64.7 miles round trip;
19 the longest distance traveled was 257.9 miles round trip.

20 28. The inspector also created a chart based on the hardcopy prescriptions showing the
21 date the prescriptions were written, drug name, strength and quantity, directions, diagnosis code,
22 and duration of the patient's treatment. The inspector determined in reviewing the prescriptions,
23 CURES information, and patient profiles that Dr. A. L.'s prescribing practices showed
24 duplication in therapy, and the same combinations of drugs were prescribed for multiple patients,
25 including fentanyl 100 mcg/h, morphine ER 100 mg or 200 mg, methadone 10 mg, oxycodone 30
26 mg, hydromorphone 8 mg, and morphine IR 30 mg. On several occasions, Dr. A. L. prescribed
27 more than one long acting opioid or short acting opioid for the patient and would prescribe short
28

1 acting opioids together. Dr. A. L. also prescribed the highest strength or dose a drug was
2 available in and prescribed large or excessive quantities of the above controlled substances.

3 **FIRST CAUSE FOR DISCIPLINE**

4 **(Failure to Exercise Corresponding Responsibility for the**
5 **Proper Prescribing and Dispensing of Controlled Substances)**

6 29. Respondent's original pharmacy permit and original pharmacist license are subject to
7 disciplinary action pursuant to Code section 4301, subdivision (o), California Health and Safety
8 Code section 11153, and California Code of Regulations, title 16, section 1761, for
9 unprofessional conduct, in that Respondent violated or attempted to violate, directly or indirectly,
10 assisted in or abetted the violation of, or conspired to violate state laws and regulations governing
11 pharmacy, as follows: On and between September 1, 2011 and September 5, 2014, Respondent,
12 as a licensed pharmacist and as the owner, operator, and pharmacist-in-charge of Live Oak
13 Pharmacy, failed to exercise his corresponding responsibility for the proper prescribing and
14 dispensing of controlled substances. Specifically, Respondent dispensed, or authorized or
15 permitted the dispensing of, numerous prescriptions for controlled substances to at least fourteen
16 different patients, all of which had been issued by Dr. A. L., when Respondent knew, or had
17 objective reason to know, that the prescriptions were not issued for a legitimate medical purpose
18 as evidenced by several "red flags" or factors, including the prescribing of large or excessive
19 quantities and doses of highly abused controlled substances, duplication of therapies for
20 individual patients, multiple patients receiving the same drugs or combinations of drugs, and the
21 distances traveled by the patients to Dr. A. L.'s office and to Live Oak Pharmacy, in violation of
22 Health and Safety Code section 11153, subdivision (a), and California Code of Regulations, title
23 16, section 1761, subdivision (b).

24 ///

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SECOND CAUSE FOR DISCIPLINE

(Failure by Pharmacist-in-Charge to Ensure Pharmacy's Compliance With All State and Federal Laws and Regulations Pertaining to the Practice of Pharmacy)

30. Respondent's original pharmacist license is subject to disciplinary action pursuant to Code section 4113, subdivision (c), and California Code of Regulations, title 16, section 1709.1, subdivision (b), in that on and between September 1, 2011 and September 5, 2014, Respondent, as the pharmacist-in-charge of Live Oak Pharmacy, failed to ensure Live Oak Pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy. The facts and circumstances are described with more particularity in paragraph 29, above.

MATTERS IN AGGRAVATION

31. On or about September 30, 2015, Respondent was issued a citation for: (1) failing to comply with California Code of Regulations, title 16, section 1716, which prohibits a pharmacist from deviating from the requirements of a prescription except upon prior consent of the prescriber; and (2) failing to comply with California Code of Regulations, title 16, section 1711(f), which requires all pharmacies to participate in an established quality assurance program which documents and assesses medication errors to determine cause and an appropriate response, and to keep a record of quality assurance review for at least one year from the date the record was created.

32. On or about September 30, 2015, Registered Pharmacist Harinder S. Rai, while employed as a pharmacist by Respondent, was issued two citations for: (1) failing to comply with California Code of Regulations, title 16, section 1716, which prohibits a pharmacist from deviating from the requirements of a prescription except upon prior consent of the prescriber; and (2) failing to comply with California Code of Regulations, title 16, section 1711(f), which requires all pharmacies to participate in an established quality assurance program which documents and assesses medication errors to determine cause and an appropriate response, and to keep a record of quality assurance review for at least one year from the date the record was created.

///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

OTHER MATTERS

33. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number PHY 45317 issued to Live Oak Pharmacy, Ranjit Singh Owner/Pharmacist-In-Charge, Ranjit Singh shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 45317 is placed on probation or until Pharmacy Permit Number PHY 45317 is reinstated if it is revoked.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1. Revoking or suspending Original Pharmacy Permit Number PHY 45317, issued to Ranjit Singh, owner and pharmacist-in-charge of Live Oak Pharmacy;
- 2. Revoking or suspending Original Pharmacist License Number RPH 46870, issued to Ranjit Singh;
- 3. Prohibiting Ranjit Singh from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY 45317 is placed on probation or until Pharmacy Permit Number PHY 45317 is reinstated if Pharmacy Permit Number 45317 issued to Live Oak Pharmacy is revoked;
- 4. Ordering Ranjit Singh, individually, and as the owner and pharmacist-in-charge of Live Oak Pharmacy, to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and
- 5. Taking such other and further action as deemed necessary and proper.

DATED: 2/2/17

Virginia Herold

VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

SA2015104280

1 KAMALA D. HARRIS
Attorney General of California
2 KENT D. HARRIS
Supervising Deputy Attorney General
3 PHILLIP L. ARTHUR
Deputy Attorney General
4 State Bar No. 238339
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 322-0032
Facsimile: (916) 327-8643
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:
12 **LIVE OAK PHARMACY**
13 **RANJIT SINGH, Owner/Pharmacist-In-Charge**
14 **9970 Live Oak Blvd.**
15 **Live Oak, CA 95953**
16 **Original Pharmacy Permit No. PHY 45317**
17 **and**
18 **RANJIT SINGH**
19 **3215 Pennington Road**
20 **Live Oak, CA 95953**
21 **Original Pharmacist License No. RPH 46870**
22 **Respondents.**

Case No. 5527

ACCUSATION

21 Complainant alleges:

22 **PARTIES**

- 23 1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity
24 as the Executive Officer of the Board of Pharmacy ("Board"), Department of Consumer Affairs.
25 2. On or about April 12, 2001, the Board issued Original Pharmacy Permit Number
26 PHY 45317 to Ranjit Singh ("Respondent"), owner and pharmacist-in-charge of Live Oak
27 Pharmacy. The original pharmacy permit was in full force and effect at all times relevant to the
28 charges brought herein and will expire on April 1, 2016, unless renewed.

1 3. On or about March 7, 1994, the Board issued Original Pharmacist License Number
2 RPH 46870 to Respondent. The original pharmacist license was in full force and effect at all
3 times relevant to the charges brought herein and will expire on March 31, 2016, unless renewed.

4 **JURISDICTION**

5 4. This Accusation is brought before the Board under the authority of the following
6 laws. All section references are to the Business and Professions Code (Code) unless otherwise
7 indicated.

8 5. Code section 4300 states, in pertinent part:

9 (a) Every license issued may be suspended or revoked.

10 (b) The board shall discipline the holder of any license issued by the
11 board, whose default has been entered or whose case has been heard by the board and
found guilty, by any of the following methods:

12 (1) Suspending judgment.

13 (2) Placing him or her upon probation.

14 (3) Suspending his or her right to practice for a period not exceeding one
15 year.

16 (4) Revoking his or her license.

17 (5) Taking any other action in relation to disciplining him or her as the
board in its discretion may deem proper

18 6. Code section 4300.1 states:

19 The expiration, cancellation, forfeiture, or suspension of a board-issued
20 license by operation of law or by order or decision of the board or a court of law, the
placement of a license on a retired status, or the voluntary surrender of a license by a
21 licensee shall not deprive the board of jurisdiction to commence or proceed with any
investigation of, or action or disciplinary proceeding against, the licensee or to render
22 a decision suspending or revoking the license.

23 **STATUTORY AND REGULATORY PROVISIONS**

24 7. Code section 4301 states, in pertinent part:

25 The board shall take action against any holder of a license who is guilty
26 of unprofessional conduct or whose license has been procured by fraud or
misrepresentation or issued by mistake. Unprofessional conduct shall include, but is
27 not limited to, any of the following:

28 . . .

1 (o) Violating or attempting to violate, directly or indirectly, or assisting in
2 or abetting the violation of or conspiring to violate any provision or term of this
3 chapter or of the applicable federal and state laws and regulations governing
4 pharmacy, including regulations established by the board or by any other state or
5 federal regulatory agency

6 8. Code section 4113, subdivision (c), states that, “[t]he pharmacist-in-charge shall be
7 responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining
8 to the practice of pharmacy.”

9 9. Health and Safety Code section 11153, subdivision (a), states, in pertinent part:

10 A prescription for a controlled substance shall only be issued for a
11 legitimate medical purpose by an individual practitioner acting in the usual course of
12 his or her professional practice. The responsibility for the proper prescribing and
13 dispensing of controlled substances is upon the prescribing practitioner, but a
14 corresponding responsibility rests with the pharmacist who fills the prescription

15 10. California Code of Regulations, title 16, section 1709.1, subdivision (a), states that,
16 “[t]he pharmacist-in-charge of a pharmacy shall be employed at that location and shall have
17 responsibility for the daily operation of the pharmacy.”

18 11. California Code of Regulations, title 16, section 1761, states:

19 (a) No pharmacist shall compound or dispense any prescription which
20 contains any significant error, omission, irregularity, uncertainty, ambiguity or
21 alteration. Upon receipt of any such prescription, the pharmacist shall contact the
22 prescriber to obtain the information needed to validate the prescription.

23 (b) Even after conferring with the prescriber, a pharmacist shall not
24 compound or dispense a controlled substance prescription where the pharmacist
25 knows or has objective reason to know that said prescription was not issued for a
26 legitimate medical purpose.

27 COST RECOVERY

28 12. Code section 125.3 provides, in pertinent part, that a Board may request the
administrative law judge to direct a licentiate found to have committed a violation or violations of
the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
enforcement of the case.

CONTROLLED SUBSTANCES

13. “Methadone” is a Schedule II controlled substance as designated by Health and
Safety Code section 11055, subdivision (c)(14).

///

1 14. "Morphine Sulfate IR (immediate release)" is a Schedule II controlled substance as
2 designated by Health and Safety Code section 11055, subdivision (b)(1)(L).

3 15. "Morphine Sulfate ER (extended release)" is a Schedule II controlled substance as
4 designated by Health and Safety Code section 11055, subdivision (b)(1)(L).

5 16. "Oxycodone" is a Schedule II controlled substance as designated by Health and
6 Safety Code section 11055, subdivision (b)(1)(M).

7 17. "Hydromorphone" is a Schedule II controlled substance as designated by Health and
8 Safety Code section 11055, subdivision (b)(1)(J).

9 18. "Fentanyl" is a Schedule II controlled substance as designated by Health and Safety
10 Code section 11055, subdivision (c)(8).

11 19. "Norco" is a compound consisting of 10 mg hydrocodone bitartrate, also known as
12 dihydrocodeinone, and 325 mg acetaminophen per tablet. At the time of the incidents described
13 below, Norco was classified as a Schedule III controlled substance pursuant to Health and Safety
14 Code section 11056, subdivision (e)(4).¹

15 STATEMENT OF FACTS

16 20. On or about November 15, 2013, the Medical Board of California revoked Dr. A. L.'s
17 physician's and surgeon's certificate. The revocation was stayed and Dr. A. L. was placed on
18 probation for five years. Dr. A. L. was also suspended from the practice of medicine for thirty
19 days. Dr. A. L. was charged in the disciplinary proceeding with prescribing excessive amounts
20 and high doses of controlled substances.

21 21. The Drug Enforcement Administration had commenced an investigation of Dr. A. L.
22 and the pharmacies that filled prescriptions for Dr. A. L.'s patients (the investigation was
23 subsequently halted due to the death of Dr. A. L. in December 2013).

24 22. A Board analyst ran CURES² reports showing Dr. A. L.'s prescribing habits. Live
25

26 ¹ Hydrocodone has been rescheduled from a Schedule III to Schedule II controlled
substance via the Controlled Substances Act (21 CFR Part 1308 § 1308.12; 21 U.S.C. 812 (c).)

27 ² CURES is a database containing information on Schedule II through IV controlled
28 substances dispensed in California. It is a valuable investigative, preventive, and educational tool
for the healthcare community, regulatory boards, and law enforcement.

1 Oak Pharmacy was identified as one of two pharmacies dispensing the most prescriptions for Dr.
2 A. L.'s patients. Dr. A. L.'s practice was located in Colusa, California, approximately 32.9 miles
3 from Live Oak Pharmacy.

4 23. On or about September 1, 2014, a Board Inspector obtained CURES information from
5 September 1, 2011 to September 5, 2014, for Live Oak Pharmacy and three other pharmacies
6 located in close proximity to Live Oak Pharmacy. The inspector selected certain patients,
7 identified in the CURES report for Live Oak Pharmacy to review based on the distance the
8 patients lived from the pharmacy, the quantities of controlled substances prescribed, the
9 combinations of controlled substances prescribed, and whether the individuals were patients of
10 Dr. A. L. The inspector also requested CURES data from September 1, 2011 to September 5,
11 2014, for each patient selected, including the following fourteen patients: TB, PM, JB, DS, MH,
12 RB, BN, KS, DM, CF, DB, JY, TF1, and TF2.

13 24. On or about September 3, 2014, the inspector and another representative of the Board
14 conducted an inspection of Live Oak Pharmacy during which they were assisted by Respondent.
15 The inspector requested patient profiles for the above fourteen patients, and found in reviewing
16 the profiles that nine of the fourteen patients were from out of the area, including Shasta Lake,
17 California (113 miles away) and Granite Bay, California (fifty-six miles away). The inspector
18 obtained several hardcopy prescriptions for thirteen of the fourteen patients and requested drug
19 utilization reports (DUR's) for Dr. A. L. from January 1, 2012 to September 3, 2014. On or about
20 September 24, 2014, the inspector received the DUR's from Respondent.

21 25. The inspector reviewed the CURES reports for Live Oak Pharmacy and the three
22 other pharmacies located in close proximity to Live Oak Pharmacy, and created spreadsheets
23 based on the data. The inspector compared the total number of controlled substances dispensed
24 by the pharmacies with the total number of controlled substances written by Dr. A. L. for the
25 period from September 1, 2011 to September 5, 2014, and found that Live Oak Pharmacy
26 dispensed more of Dr. A. L.'s prescriptions than any of the other pharmacies.

27 26. The inspector created a chart showing the round trip distance from the fourteen
28 patients' homes to Dr. A. L.'s office in Colusa and Live Oak Pharmacy. Only five of the fourteen

1 patients lived in Live Oak Pharmacy's trade area, defined by Respondent as Yuba City, Gridley,
2 and Live Oak. The shortest distance traveled for the fourteen patients was 64.7 miles round trip;
3 the longest distance traveled was 257.9 miles round trip.

4 27. The inspector also created a chart based on the hardcopy prescriptions showing the
5 date the prescriptions were written, drug name, strength and quantity, directions, diagnosis code,
6 and duration of the patient's treatment. The inspector determined in reviewing the prescriptions,
7 CURES information, and patient profiles that Dr. A. L.'s prescribing practices showed
8 duplication in therapy, and the same combinations of drugs were prescribed for multiple patients,
9 including fentanyl 100 mcg/h, morphine ER 100 mg or 200 mg, methadone 10 mg, oxycodone 30
10 mg, hydromorphone 8 mg, and morphine IR 30 mg. On several occasions, Dr. A. L. prescribed
11 more than one long acting opioid or short acting opioid for the patient and would prescribe short
12 acting opioids together. Dr. A. L. also prescribed the highest strength or dose a drug was
13 available in and prescribed large or excessive quantities of the above controlled substances.

14 **FIRST CAUSE FOR DISCIPLINE**

15 **(Failure to Exercise Corresponding Responsibility for the**
16 **Proper Prescribing and Dispensing of Controlled Substances)**

17 28. Respondent's original pharmacy permit and original pharmacist license are subject to
18 disciplinary action pursuant to Code section 4301, subdivision (o), California Health and Safety
19 Code section 11153, and California Code of Regulations, title 16, section 1761, for
20 unprofessional conduct, in that Respondent violated or attempted to violate, directly or indirectly,
21 assisted in or abetted the violation of, or conspired to violate state laws and regulations governing
22 pharmacy, as follows: On and between September 1, 2011 and September 5, 2014, Respondent,
23 as a licensed pharmacist and as the owner, operator, and pharmacist-in-charge of Live Oak
24 Pharmacy, failed to exercise his corresponding responsibility for the proper prescribing and
25 dispensing of controlled substances. Specifically, Respondent dispensed, or authorized or
26 permitted the dispensing of, numerous prescriptions for controlled substances to at least fourteen
27 different patients, all of which had been issued by Dr. A. L., when Respondent knew, or had
28 objective reason to know, that the prescriptions were not issued for a legitimate medical purpose

1 as evidenced by several “red flags” or factors, including the prescribing of large or excessive
2 quantities and doses of highly abused controlled substances, duplication of therapies for
3 individual patients, multiple patients receiving the same drugs or combinations of drugs, and the
4 distances traveled by the patients to Dr. A. L.’s office and to Live Oak Pharmacy, in violation of
5 Health and Safety Code section 11153, subdivision (a), and California Code of Regulations, title
6 16, section 1761, subdivision (b).

7 **SECOND CAUSE FOR DISCIPLINE**

8 **(Failure by Pharmacist-in-Charge to Ensure Pharmacy’s Compliance With All State and**
9 **Federal Laws and Regulations Pertaining to the Practice of Pharmacy)**

10 29. Respondent’s original pharmacist license is subject to disciplinary action pursuant to
11 Code section 4113, subdivision (c), and California Code of Regulations, title 16, section 1709.1,
12 subdivision (b), in that on and between September 1, 2011 and September 5, 2014, Respondent,
13 as the pharmacist-in-charge of Live Oak Pharmacy, failed to ensure Live Oak Pharmacy’s
14 compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.
15 The facts and circumstances are described with more particularity in paragraph 28, above.

16 **MATTERS IN AGGRAVATION**

17 30. On or about September 30, 2015, Respondent was issued a citation for: (1) failing to
18 comply with California Code of Regulations, title 16, section 1716, which prohibits a pharmacist
19 from deviating from the requirements of a prescription except upon prior consent of the
20 prescriber; and (2) failing to comply with California Code of Regulations, title 16, section
21 1711(f), which requires all pharmacies to participate in an established quality assurance program
22 which documents and assesses medication errors to determine cause and an appropriate response,
23 and to keep a record of quality assurance review for at least one year from the date the record was
24 created.

25 31. On or about September 30, 2015, Registered Pharmacist Harinder S. Rai, while
26 employed as a pharmacist by Respondent, was issued two citations for: (1) failing to comply with
27 California Code of Regulations, title 16, section 1716, which prohibits a pharmacist from
28 deviating from the requirements of a prescription except upon prior consent of the prescriber; and

1 (2) failing to comply with California Code of Regulations, title 16, section 1711(f), which
2 requires all pharmacies to participate in an established quality assurance program which
3 documents and assesses medication errors to determine cause and an appropriate response, and to
4 keep a record of quality assurance review for at least one year from the date the record was
5 created.

6 **PRAYER**

7 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
8 and that following the hearing, the Board of Pharmacy issue a decision:

- 9 1. Revoking or suspending Original Pharmacy Permit Number PHY 45317, issued to
10 Ranjit Singh, owner and pharmacist-in-charge of Live Oak Pharmacy;
- 11 2. Revoking or suspending Original Pharmacist License Number RPH 46870, issued to
12 Ranjit Singh;
- 13 3. Ordering Ranjit Singh, individually, and as the owner and pharmacist-in-charge of
14 Live Oak Pharmacy, to pay the Board of Pharmacy the reasonable costs of the investigation and
15 enforcement of this case, pursuant to Business and Professions Code section 125.3; and
- 16 4. Taking such other and further action as deemed necessary and proper.

17
18 DATED: _____

3/25/16



19 VIRGINIA HEROLD
20 Executive Officer
21 Board of Pharmacy
22 Department of Consumer Affairs
23 State of California
24 Complainant

25
26
27
28 SA2015104280